Psychiatry and Neurology, Neurology with Special Qualifications in Child Neurology · Edison, NJ
NPI
1326145764
Since 2006
Specialty
Psychiatry and Neurology, Neurology with Special Qualifications in Child Neurology
Code 2084N0402X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
98 James Street, Suite 301
Edison, NJ, 08820
Phone (732) 738-8830
Groups this clinician bills Medicare through
Medicare paid, 2024
$102K
1,604 services
Medicare patients, 2024
363
Average age 73
Drug cost, 2024
$2.1M
2,302 prescriptions
Company payments, 2025
$143
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mohammed F Nizam was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 709 times for 340 patients. In total Mohammed F Nizam billed 1,604 services in 20 codes, and Medicare paid $102K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-02-18.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 709 | 340 | $12.16 | $8,621 |
| 99214 Office E&M - Established | Office | 435 | 222 | $92.23 | $40K |
| 99213 Office E&M - Established | Office | 191 | 134 | $59.94 | $11K |
| 99204 Office E&M - New | Office | 76 | 76 | $128.36 | $9,756 |
| 95816 Neurologic | Office | 34 | 33 | $340.37 | $12K |
| 99203 Office E&M - New | Office | 30 | 30 | $87.48 | $2,625 |
| 95911 Electrical Nerve Conductivity | Office | 14 | 14 | $173.57 | $2,430 |
| 93880 Duplex Scan - Extracranial Arteries | Office | 13 | 13 | $141.73 | $1,843 |
| 93890 Ultrasound - Nonspecific | Office | 13 | 13 | $235.96 | $3,068 |
| 93886 Ultrasound - Nonspecific | Office | 13 | 13 | $223.93 | $2,911 |
| 93892 Ultrasound - Nonspecific | Office | 12 | 12 | $141.97 | $1,704 |
By year: 2022 $156K for 1,238 services; 2023 $178K for 1,413 services; 2024 $102K for 1,604 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mohammed F Nizam prescribed most often to Medicare patients was Gabapentin, with 193 prescriptions and refills. In total Mohammed F Nizam wrote 2,302 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 193 | 298 | 42 | $4,048 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 185 | 288 | 42 | $3,239 |
| Topiramate Generic | 154 | 233 | 23 | $1,459 |
| Levetiracetam Generic | 131 | 255 | 27 | $5,003 |
| Ubrelvy Ubrogepant | 105 | 105 | 18 | $106K |
| Donepezil Hcl Generic | 93 | 188 | 23 | $1,237 |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 65 | 101 | 13 | $3,192 |
| Oxcarbazepine Generic | 61 | 69 | Under 11 | $2,825 |
| Memantine Hcl Generic | 60 | 114 | 16 | $2,238 |
| Carbamazepine Generic | 51 | 77 | Under 11 | $2,746 |
| Cyclobenzaprine Hcl Generic | 50 | 50 | 11 | $267 |
| Nurtec Odt Rimegepant Sulfate | 49 | 49 | Under 11 | $47K |
| Primidone Generic | 43 | 76 | 13 | $568 |
| Qulipta Atogepant | 42 | 42 | Under 11 | $45K |
| Pregabalin Generic | 42 | 47 | Under 11 | $1,325 |
Brand drugs: 385 claims; generic drugs: 1,895 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mohammed F Nizam $143 ($143 in general payments such as food, travel and fees) from 1 company. The largest payer was Abbvie Inc. with $143.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 19 | $143 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.